Premium
Cannabis use does not impact on type 2 diabetes: A two‐sample Mendelian randomization study
Author(s) -
Baumeister SebastianEdgar,
Nolde Michael,
Alayash Zoheir,
Leitzmann Michael,
Baurecht Hansjörg,
Meisinger Christa
Publication year - 2021
Publication title -
addiction biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.445
H-Index - 78
eISSN - 1369-1600
pISSN - 1355-6215
DOI - 10.1111/adb.13020
Subject(s) - mendelian randomization , type 2 diabetes , cannabis , odds ratio , single nucleotide polymorphism , medicine , confidence interval , diabetes mellitus , psychiatry , genetics , biology , endocrinology , genotype , gene , genetic variants
Cannabis has effects on the insulin/glucose metabolism. As the use of cannabis and the prevalence of type 2 diabetes increase worldwide, it is important to examine the effect of cannabis on the risk of diabetes. We conducted a Mendelian randomization (MR) study by using 19 single‐nucleotide polymorphisms (SNPs) as instrumental variables for lifetime cannabis use and 14 SNPs to instrument cannabis use disorder and linking these to type 2 diabetes risk using genome‐wide association study data (lifetime cannabis use [ N = 184,765]; cannabis use disorder [2387 cases/48,985 controls], type 2 diabetes [74,124 cases/824,006 controls]). The MR analysis suggested no effect of lifetime cannabis use (inverse‐variance weighted odds ratio [95% confidence interval] = 1.00 [0.93–1.09], P value = 0.935) and cannabis use disorder (OR = 1.03 [0.99–1.08]) on type 2 diabetes. Sensitivity analysis to assess potential pleiotropy led to no substantive change in the estimates. This study adds to the evidence base that cannabis use does not play a causal role in type 2 diabetes.